Reality Check on Ankylosing Spondylitis
Market access for ankylosing spondylitis treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 69% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: The FDA’s recent approvals of two interleukin-17A (IL-17A) antagonists — Eli Lilly and Co.’s Taltz (ixekizumab) and Novartis Pharmaceuticals Corp.’s Cosentyx (secukinumab) — to treat active non-radiographic axial spondyloarthritis, a less advanced form of ankylosing spondylitis, provide a new mechanism of action
- Key Findings: Contracting is everything in this indication. Payers and PBMs often partner with franchises across immunology indications. Competitive contracting situations are everywhere. Biosimilars are in trials and coming to the U.S. market, where they will be large competitors for brands
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.